Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 20/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12590928 | 1.00 | PTGES (0.59) | PTGESTBXAS1JAK2 | |
| SCHEMBL12590891 | 0.90 | PTGES (0.65) | PTGESTBXAS1JAK2 | |
| SCHEMBL1758039 | 0.85 | PTGES (0.65) | PTGESTBXAS1JAK2 | |
| SCHEMBL13750231 | 0.83 | PTGES (0.63) | PTGESTBXAS1JAK2 | |
| SCHEMBL12329985 | 0.83 | PTGES (0.80) | PTGESTBXAS1JAK2 | |
| SCHEMBL12590917 | 0.83 | PTGES (0.63) | PTGESTBXAS1JAK2 | |
| SCHEMBL12590902 | 0.82 | PTGES (0.67) | PTGESTBXAS1 | |
| SCHEMBL1758301 | 0.80 | PTGES (0.81) | PTGESTBXAS1JAK2 | |
| SCHEMBL1758837 | 0.80 | PTGES (0.81) | PTGESTBXAS1JAK2 | |
| SCHEMBL4049140 | 0.80 | PTGES (0.91) | PTGESJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943649-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2011-05-17 | — | — | US | disclosed |
| US-20090203922-A1 | Process for Synthesizing 2-Phenyl-1H-Phenanthro[9,10-d]Imidazole Derivative | MERCK SHARP & DOHME CORP. | 2009-08-13 | — | — | US | disclosed |
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | MERCK FROSST CANADA LTD. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090111997-A1 | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals | MERCK SHARP & DOHME CORP. | 2009-04-30 | — | — | US | disclosed |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2009-03-19 | — | — | US | disclosed |
| US-7442716-B2 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK FROSST CANADA LTD. (CA) | 2008-10-28 | — | — | US | disclosed |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | MERCK CANADA INC. (CA) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192158-A1 | Methods for Treating or Preventing Neoplasias | GSTO1, PTGS1, PTGES | PTGES 3/4885TBXAS1 368/4885JAK2 4092/4885 |
| US-20070208017-A1 | 2-(Phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | PTGES 2/4885TBXAS1 154/4885JAK2 1417/4885 |
| US-20090203922-A1 | Process for Synthesizing 2-Phenyl-1H-Phenanthro[9,10-d]Imidazole Derivative | PTGES, PTGS1, PTGES2 | PTGES 1/4885TBXAS1 189/4885JAK2 2419/4885 |
| US-20090111997-A1 | Method of Generating Amorphous Solid for Water-Insoluble Pharmaceuticals | WDR33, POLR2H, NSF | PTGES 3434/4885TBXAS1 3766/4885JAK2 128/4885 |
| US-20090075998-A1 | 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors | PTGS1, PTGES, PTGES2 | PTGES 2/4885TBXAS1 154/4885JAK2 1417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.